Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer

MLA

Kelly Jones, et al. “Dose-Limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.” International Journal of Radiation Oncology*Biology*Physics, vol. 101, Aug. 2018, pp. 1168–71. EBSCOhost, https://doi.org/10.1016/j.ijrobp.2018.04.070.

APA

Kelly Jones, Robert Huddart, Mansour T. A. Sharabiani, Susan Lalondrelle, Merina Ahmed, Kevin J. Harrington, Alison Tree, & Shaista Hafeez. (2018). Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer. International Journal of Radiation Oncology*Biology*Physics, 101, 1168–1171. https://doi.org/10.1016/j.ijrobp.2018.04.070

Chicago

Kelly Jones, Robert Huddart, Mansour T. A. Sharabiani, Susan Lalondrelle, Merina Ahmed, Kevin J. Harrington, Alison Tree, and Shaista Hafeez. 2018. “Dose-Limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.” International Journal of Radiation Oncology*Biology*Physics 101 (August): 1168–71. doi:10.1016/j.ijrobp.2018.04.070.